Autism Disorder & Treatment Market Report – Global Forecast Till 2023


Autism Disorder & Treatment Market Information: By Type (Asperger Syndrome, Pervasive Developmental Disorder, Others), by Treatment Type (Aba, Hyperbaric Oxygen Therapy, and Others), by Drug (SSRIs, Anti-Convulsant, Others) – Global Forecast Till 2023


Market Analysis
Autism or Autism Spectrum Disorder (ASD)is a type of condition that is caused by major challenges like difficulties with speech, social skills, verbal and nonverbal communication, along with showing the signs of repetitive behaviors and various other strengths and unique differences. This condition is caused by various combinations of hereditary and natural influences. Autism is generally seen in children somewhere under the age group of two to three years. In different cases, it tends to be analyzed within a year or 18 months of birth. Global Autism Disorder & Treatment Market is projected to grow at a CAGR of 4.37% during the forecast period 2017–2023.
Growing awareness about autism amongst the affected population and the increasing prevalence of autism and Pervasive Developmental Disorder (PDD) is boosting the growth of the global autism disorder and treatment market. Autism disorder issue and treatment is seen as one of the prominently developing markets in the healthcare division due to the initiatives and other healthcare activities conducted by the government of different countries and expected endorsements of different off-name treatment treatments by the Food and Drug Association (FDA). With the upsurge in the market, there are a few restraints that are faced by the Global autism disorder & treatment market, for example, a powerless pipeline of drugs for autism disorder and obscure pathophysiology and etiology of ASD.
Market Segmentation
The Global autism disorder & treatment market is classified on the basis of its type, drugs and treatment type. On the basis of its type, the market is segmented into Pervasive Developmental Disorder, Asperger Syndrome, and others. By treatment type, the market is sectioned into hyperbaric oxygen therapy, oxytocin therapy, ABA (applied behavioral analysis), chelation therapy, and others. Based on its drug type, the market is divided into SSRIs, stimulants, anti-convulsant, anti-psychotic.
Regional Analysis
Geographically, the Global autism disorder & treatment market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.
Major Players
Some of the major industry players in the Global autism disorder & treatment market include companies like Pfizer Inc., Allergan, Eli Lilly and Company, Saniona AB, Merck & CO Inc., Consern Pharma Private Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Bristol-Myers Squibb and Otsuka Holdings Co., Ltd., Johnson & Johnson Services, Inc., Coronis Partners Ltd., Heptares Therapeutics Limited, Curemark LLC, Intra-Cellular Therapies Inc., among others.

Additional information


Geography Covered

Date Published



Table of Contents

Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Scope of Study
2.2 Research Objective
2.3 Assumptions & Limitations
2.3.1 Assumptions
2.3.2 Limitations
3 Research Methodology
3.1 Primary Research Methodology
3.2 Secondary Research Methodology
3.3 Market Share Analysis
3.4 Trade Analysis
3.5 Market Pricing Approach
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Rising Prevalence of Autism Disorder and Pervasive Developmental Disorder Have Fueled the Growth of the Market.(PDD)
4.2.2 Expected Approvals of Off-Label Drugs to Treat Autism Disorder Has Driven the Market Growth
4.2.3 Rising government or privately held societies taking initiatives to create the awareness about the disease
4.3 Restraints
4.3.1 Weak Product Pipeline of First Drugs for Autism
4.3.2 Unknown Etiology and Pathophysiology of the Disorder Prevent Effective Treatment Options
4.4 Opportunities
4.4.1 Rising Investments by Venture Non-Pharmacology Activities
4.5 Mega Trends
4.6 Macroeconomic Indicators
5 Market Factor Analysis
5.1 Porter’s Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 R&D
5.2.2 Manufacturing
5.2.3 Distribution & Sales
5.2.4 Post-Sales Monitoring
5.3 Pricing Analysis
5.4 Investment Opportunity Analysis
5.5 Demand & Supply: Gap Analysis
6 Global Autism Disorder & Treatment Market, By Type
6.1 Introduction
6.2 Asperger Syndrome
6.3 Pervasive Developmental Disorders (PDD)
7 Global Autism Disorder & Treatment Market, By Treatment Type
7.1 Introduction
7.2 Expert Opinion: Oxytocin
7.3 ABA (applied behavioral analysis)
7.4 Hyperbaric oxygen therapy
7.5 Chelation therapy
7.6 Oxytocin therapy
8 Global Autism Disorder & Treatment Market, By Drugs
8.1 Introduction
8.2 Selective Serotonin Reuptake Inhibitors (SSRIs)
8.3 Anti-convulsants
8.4 Stimulants
8.5 Anti-psychotic
9 Global Autism Disorder & Treatment Market, By Region
9.1 Introduction
9.2 Americas
9.3 North America
9.3.1 U.S.
9.4 Canada
9.4.1 South America
9.5 Europe
9.5.1 Germany
9.5.2 France
9.5.3 U.K.
9.5.4 Italy
9.5.5 Spain
9.5.6 Rest of Western Europe
9.5.7 Eastern Europe
9.6 Asia Pacific
9.6.1 Japan
9.6.2 China
9.6.3 India
9.6.4 Australia
9.6.5 Republic of Korea
9.6.6 Rest of Asia Pacific
9.7 Middle East & Africa
9.7.1 U.A.E.
9.7.2 Saudi Arabia
9.7.3 Oman
9.7.4 Kuwait
9.7.5 Qatar
9.7.6 Rest of the Middle East & Africa
10 Competitive Landscape
10.1 Company Market Share Analysis
10.1.1 Introduction
10.2 Competitive Landscape
10.2.1 Introduction
10.3 Recent Developments, 2013–2018
11 Company Profiles
11.1 Pfizer Inc.
11.1.1 Company Overview
11.1.2 Financials
11.1.3 Products
11.1.4 Strategy
11.1.5 Key Developments
11.2 Allergan, Plc
11.2.1 Company Overview
11.2.2 Financials
11.2.3 Products
11.2.4 Strategy
11.2.5 Key Developments
11.3 Eli Lilly and Company
11.3.1 Company Overview
11.3.2 Financials
11.3.3 Products
11.3.4 Strategy
11.3.5 Key Developments
11.4 Bristol-Myers Squibb Company
11.4.1 Company Overview
11.4.2 Financials
11.4.3 Products
11.4.4 Strategy
11.4.5 Key Developments
11.5 Sun Pharmaceutical Industries Ltd.
11.5.1 Company Overview
11.5.2 Financials
11.5.3 Products
11.5.4 Strategy
11.5.5 Key Developments
11.6 Johnson & Johnson Services, Inc.
11.6.1 Company Overview
11.6.2 Financials
11.6.3 Products
11.6.4 Strategy
11.6.5 Key Developments
11.7 Teva Pharmaceutical Industries Ltd.
11.7.1 Company Overview
11.7.2 Financials
11.7.3 Products
11.7.4 Strategy
11.7.5 Key Developments

11.8 Merck & Co. Inc
11.8.1 Company Overview
11.8.2 Financials
11.8.3 Products
11.8.4 Strategy
11.8.5 Key Developments
11.9 Novartis AG
11.9.1 Company Overview
11.9.2 Financials
11.9.3 Products
11.9.4 Strategy
11.9.5 Key Developments
11.1 Otsuka Holdings Co. Ltd
11.10.1 Company Overview
11.10.2 Financials
11.10.3 Products
11.10.4 Strategy
11.10.5 Key Developments
11.11 Consern Pharma Private Limited
12 Conclusion
12.1 Key Findings
12.1.1 CEO’s Viewpoint
12.1.2 Key Companies to Watch
12.1.3 Prediction of Dietary Supplements in an Age of Personalized Nutrition Industry
13 Appendix
13.1 Discussion Blue Print
13.2 Expert Opinion: Oxytocin
13.3 References